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Abstract
Background: Testosterone (T) deficiency remains a poorly understood issue in men with Human Immunodeficiency Virus
(HIV). We investigated the gonadal status in HIV-infected men in order to characterize T deficiency and to identify predictive
factors for low serum T.
Methodology/Principal Findings: We performed a cross-sectional, observational study on 1325 consecutive HIV male
outpatients, most of them having lipodystrophy. Serum total T,300 ng/dL was used as the threshold for biochemical T
deficiency. Morning serum total T, luteinizing hormone (LH), estradiol, HIV parameters, and body composition parameters
by CT-scan and Dual-Energy-X-ray-Absorptiometry were measured in each case. Sexual behavior was evaluated in a subset
of 247 patients. T deficiency was found in 212 subjects, especially in the age range 40–59, but was frequent even in younger
patients. T deficiency occurred mainly in association with low/normal serum LH. Adiposity was higher in subjects with T
deficiency (p,0.0001) and both visceral adipose tissue and body mass index were the main negative predictors of serum
total T. Osteoporosis and erectile dysfunction were present in a similar percentage in men with or without T deficiency.
Conclusions/Significance: Premature decline of serum T is common (16%) among young/middle-aged HIV-infected men
and is associated with inappropriately low/normal LH and increased visceral fat. T deficiency occurs at a young age and may
be considered an element of the process of premature or accelerated aging known to be associated with HIV infection. The
role of HIV and/or HIV infection treatments, as well as the role of the general health state on the gonadal axis, remains, in
fact, to be elucidated. Due to the low specificity of signs and symptoms of hypogonadism in the context of HIV, caution is
needed in the diagnosis of hypogonadism in HIV-infected men with biochemical low serum T levels.
Citation: Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, et al. (2011) Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-
Era. PLoS ONE 6(12): e28512. doi:10.1371/journal.pone.0028512
Editor: Sunil K. Ahuja, South Texas Veterans Health Care System, United States of America
Received June 7, 2011; Accepted November 9, 2011; Published December 9, 2011
Copyright:  2011 Rochira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vincenzo.rochira@unimore.it
Introduction
Circulating testosterone (T) declines with advancing age [1]
especially after the age of 65 years [1–3]. The prevalence of T
deficiency in different studies varies from 13.8% [4] to 20%–25%
[5,6] and 38.7% [3], depending on different cut-off values of
serum T and different age ranges.
Androgen deficiency is common among men with human
immunodeficiency virus (HIV) infection treated with highly active
antiretroviral therapy (HAART), ranging from 20 to 30%
according to different studies [7,8]. In the past, men with acquired
immunodeficiency syndrome (AIDS) showed a high prevalence of
hypogonadism (29%–50%), mainly caused by impaired testicular
function due to both wasting syndrome and opportunistic
infections [9–12]. The introduction of HAART changed the
spectrum and modified the prevalence of several co-morbidities,
including androgen deficiency [11], which seems to occur less
frequently than in the past [9,10]. Despite its frequent occurrence,
the actual prevalence of T deficiency remains not well defined in
HIV-infected patients, ranging from 3–7% [7,12,13,14,17] to 54–
64% [15,16] in the different reports. An impairment of the
hypothalamic-pituitary axis plays a possible major role in
determining T deficiency, as suggested by the common occurrence
of low T in concomitance with inappropriately low or normal
serum luteinizing hormone (LH) in HIV-infected patients
[12,17,18]. However, the underlying causes and mechanisms
remain unknown. Previous studies on T deficiency in HIV-
infected men suffer from several limitations: i) the lack of of
information on gonadotropins in most studies [7,12,13], ii) the
small number of subjects enrolled [7,12–17], iii) the possibility of
inappropriate blood sampling [7,13–16] e.g. not considering
serum T diurnal variations [19], iv) the measurement of free T
alone [7,16] by inaccurate assays [20], v) the retrospective design
only from record charts [14], and, finally, vi) the lack of studies
with an endocrinological rather than infectivological focus. These
limitations weaken the evidence regarding T deficiency in HIV-
infected men. As a result, clinical evidence resulting in the form of
guidelines [21] or expert-based opinions [8,22] is scarce.
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At present, clinical practice guidelines for androgen deficiency
recognize that HIV-infected men could be at higher risk of low
serum T and perhaps of developing overt hypogonadism and
indicate that T replacement treatment may be useful as an
adjunctive therapy in HIV-infected men with low serum T but
only in those with concomitant weight loss [21]. In subjects
without HIV T deficiency is usually defined by investigating the
hypothalamic pituitary-testicular axis. Accordingly, it is possible to
differentiate primary hypogonadism (testicular failure) from
secondary hypogonadism (gonadotropin deficiency) by measuring
gonadotropin serum levels [21,22]. In addition, several factors
such as obesity or a poor health status could affect the
hypothalamic-pituitary-gonadal axis in men [4,6,21,22]. However,
a systematic evaluation of T deficiency occurring in HIV-infected
patients is still lacking, and the only available data come from
small subsets of patients. Given the high frequency of T deficiency
in HIV-infected patients [7,12–17], understanding the pathophys-
iological mechanism of hypogonadism in these men, who may be
considered for androgen replacement treatment, is essential for a
rational treatment.
At present, two measurements of serum total T obtained in the
morning (at 8 AM) documenting a T value below the lower limit of
the laboratory range are required to confirm the diagnosis of
hypogonadism [21]. The accuracy of T measurement is fairly
controversial due to several limitations of the methods employed,
especially those used for serum free T. Direct measurement of free
T with commercially available kits is, in fact, unreliable, and the
calculation of serum free T using sex hormone binding globulin
(SHBG) and total T should be preferred [20]. However, even this
parameter remains of limited value in clinical practice due to the
possible sum of errors of each assay [23]. Measurements of free T
by equilibrium dialysis and total T by tandem mass spectrometry
are regarded as the gold standard in terms of accuracy and
precision [20,21], but are still expensive and time-consuming to be
routinely used in clinical practice [23]. For these reasons, the
repeated measurement of morning serum total T remains the most
practical tool in the clinic and is the approach most widely used by
clinicians to rule out T deficiency in men [21,22,23].
Considering all the factors mentioned above, we estimated the
prevalence of low serum total T in a large cohort of HIV-infected
men, predominately men with lipodystrophy. In particular, we
evaluated T deficiency by measuring not only circulating T [21],
but also serum LH in order to use the combination of T and LH to
provide a comprehensive information on the gonadal axis function
Figure 1. Study design. E2: estradiol, PRL: prolactin, fT4: free T4, fT3: free T3.
doi:10.1371/journal.pone.0028512.g001
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[4]. Combining LH with serum total T improves understanding of
the nature of T deficiency in the context of HIV; furthermore it
may be of help in the selection of candidates for T replacement
treatment and strict monitoring. Furthermore, considering the
changes in body composition occurring in HIV-infected men
[11,12,18] and the potential impact of adiposity on the gonadal
axis, we investigated the relationships of serum T with body
composition and parameters of HIV infection and gonadotropin
secretion, with the aim of identifying possible predictive factors for
low serum T.
Methods
We performed a cross-sectional, observational study in HIV-
infected patients attending the University Hospital of Modena as
summarized in Figure 1.
Participants
Fifteen hundred consecutive HIV-infected male outpatients who
attended the Infectious Diseases Unit Metabolic Clinic for the
assessment of lipodystrophy over a period from April 2005 to May
2009 were assessed for suitability before enrollment in the study.
As lipodystrophy is very frequent among HIV-infected patients,
body composition is currently assessed in patients with or without
lipodystrophy in order to monitor prospectively body composition
changes. 1331 HIV-infected men were finally enrolled in the
study, according to the inclusion and exclusion criteria listed
below. Six patients did not complete the protocol study and a total
of 1325 patients aged 45.5567.24 years underwent all the
procedures planned by the study protocol (Figure 1).
Study Description
All subjects underwent venous blood sampling at 8 AM after an
overnight fast. All blood samples were stored at 280Cu until
assayed. The biochemical, endocrinological and anthropometric
evaluations described below were performed in each participant
enrolled according to the research protocol (Figure 1).
Table 1. Characteristics of the entire cohort as median, and
minimum and maximum in parenthesis.
n 1325 n.v. Median (Min-Max)
Age (years) - 45 (20–69)
Anthropometrical variables
Weight (kg) - 70.5 (42–135)
BMI (kg/m2) 19–25 23.62 (15.01–54.97)
Waist circumference (cm) ,94 87 (63–160)
Hip circumference (cm) ,101 89.0 (71–141)
Waist/hip circumference ratio ,0.95 0.97 (0.79–1.29)
VAT (cm2) - 129 (11–853)
SAT (cm2) - 100 (2–807)
TAT(cm2) - 237 (16–1088)
Total body fat mass (g?1.000) - 9.19 (1.10–46.23)
Trunk fat mass (g?1.000) - 5.63 (0.25–47.43)
Total body lean mass (g?1.000) - 55.47 (4.57–84.19)
Trunk lean mass (g?1.000) - 27.66 (2.45–45.43)
Biochemical measurements
Total cholesterol (mg/dL) ,200 184 (66–390)
LDL cholesterol (mg/dL) ,115 108 (32–240)
HDL cholesterol (mg/dL) .39 39 (15–80)
Triglycerides (mg/dL) ,180 184 (29–981)
Glucose (mg/dL) 70–110 91 (58–122)
Insulin (uU/mL) 2–23 14.4 (0.5–165)
Hormonal measurements
Total T (ng/dL) 300–900 452 (11–1098)
LH (mIU/mL) 1.4–8.9 5 (0.1–46.2)
FSH (mIU/mL) 1.7–6.9 4.6 (0.3–75.6)
E2 (pg/mL) 20–40 31 (4.6–98)
Prolactin (ng/mL) 2.1–17.7 6.6 (2.2–17.5)
TSH (uU/mL) 0.35–4.5 1.72 (0.53–4.3)
fT4 (ng/dL) 0.61–1.67 1.04 (0.75–1.59)
fT3 (pg/mL) 1.7–4.2 3.4 (1.78–4.05)
Bone Mineral Density
Lumbar BMD (g/cm2) - 1.07 (0.65–1.76)
Lumbar normal BMD n (%) - 714 (53.90%)
Lumbar osteopenic BMD n (%) - 494 (37.28%)
Lumbar osteporosis BMD n (%) - 117 (8.82%)
Femoral BMD (g/cm2) - 0.85 (0.32–1.41)
Femoral normal BMD n (%) - 480 (36.26%)
Femoral osteopenic BMD n (%) - 715 (53.93%)
Femoral osteporosis BMD n (%) - 130 (9.81%)
Infectivological parameters
CD4 Count (cells/mm3) .400 500 (11–2459)
CD4 nadir (cells/mm3) - 170 (0–986)
Viral Load - 50 (20–94988)
Suppressed viral load n (%) ,40 copies/mL 901 (68%)
Months of HIV infection - 175 (3–285)
Hepatitis B n (%) - 78 (5.89%)
Hepatitis C n (%) - 380 (28.68%)
Lipodystrophy – MACS score
None n (%) - 184 (13.90%)
n 1325 n.v. Median (Min-Max)
Peripheral lipoatrophy n (%) - 573 (43.20%)
Central adiposity n (%) - 123 (9.30%)
Mixed form n (%) - 445 (33.60%)
Ongoing therapy
FI n (%) - 21 (1.58%)
PI n (%) - 447 (33.74%)
NNRTI n (%) - 331 (24.98%)
NRTI n (%) - 850 (64.15%)
Time exposure to HAART
FI (months) 8 (0–45)
PI (months) 25 (0–184)
NNRTI (months) 22 (0–118)
NRTI (months) 49 (0–262)
Total duration of HAART (years) 10 (1–16)
Number of patients (n) and relative percentages (%) are reported in Italics, n.v.:
normal values: E2: estradiol, fT4: free T4, fT3: free T3, BMD: bone mineral density, FI:
fusion inhibitors, PI: protease inhibitors, NNRTI: non-nucleoside reverse
transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.
doi:10.1371/journal.pone.0028512.t001
Table 1. Cont.
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Table 2. Characteristics as median, and minimum and maximum in parenthesis, according to the two groups defined by using the
threshold of serum total T of 300 ng/dL for establishing T deficiency (the nonparametric Mann-Whitney test was used for
comparisons).
n.v. Total T$300 ng/dL Total T,300 ng/dL Sig.
n 1325 (%) 1113 (84%) 212 (16%)
Age (years) - 45 (20–69) 46 (28–68) p = 0.006
Anthropometrical variables
BMI (kg/m2) 19–25 23.37 (15.01–43.49) 25.13 (17.2–54.97) p,0.0001
Waist circumference (cm) ,94 86 (63–128) 90 (68–160) p,0.0001
Hip circumference (cm) ,101 89 (71–116) 91 (77.5–141) p,0.0001
Waist/hip circumference ratio ,0.95 0.97 (0.79–1.29) 0.99 (0.84–1.21) p,0.0001
VAT (cm2) - 124 (11–853) 151 (29–521) p,0.0001
SAT (cm2) - 97 (2–807) 124 (2–595) p,0.0001
TAT(cm2) - 230 (16–1088) 288 (56–909) p,0.0001
Total body fat mass (g?1.000) - 8.91 (1.10–46.23) 11.7 (1.95–43.42) p,0.0001
Trunk fat mass (g?1.000) - 5.43 (0.25–47.43) 6.98 (1.0–27.87) p,0.0001
Total body lean mass (g?1.000) - 55.23 (4.57–84.19) 57.34 (5.43–83.93) p = 0.002
Trunk lean mass (g?1.000) - 27.49 (2.45–43.32) 28.63 (6.35–45.43) p = 0.002
Hormonal measurements
Total T (ng/dL) 300–900 488 (300–1098) 247 (11–299) p,0.0001
LH (mIU/mL) 1.4–8.9 5.3 (1.4–46.2) 3.8 (0.1–40.8) p,0.0001
FSH (mIU/mL) 1.7–6.9 4.6 (0.3–75.6) 4.5 (0.3–42.7) p = 0.6
E2 (pg/mL) 20–40 32 (4.6–98) 23 (10–91) p,0.0001
E2/Total T - 0.0066 (0.0008–0.0219) 0.0101 (0.0036–0.8) p,0.0001
Bone Mineral Density
Lumbar BMD (g/cm2) - 1.08 (0.65–1.76) 1.07 (0.70–1.66) p = 0.7
Lumbar normal BMD n (%) - 603 (54,17%) 112 (52.84%) -
Lumbar osteopenic BMD n (%) - 411 (36,93%) 83 (39.16%) -
Lumbar osteporosis BMD n (%) - 99 (8,9%) 17 (8.0%) -
Femoral BMD (g/cm2) - 0.85 (0.32–1.41) 0.86 (0.44–1.29) p = 0.5
Femoral normal BMD n (%) - 402 (36.12%) 78 (36.8%) -
Femoral osteopenic BMD n (%) - 597 (53.64%) 117 (55.2%) -
Femoral osteporosis BMD n (%) - 114 (10.24%) 17 (8.0%) -
Infectivological parameters
CD4 Count (cells/mm3) .400 495.5 (11–1670) 525 (11–2459) p = 0.1
CD4 nadir (cells/mm3) - 166 (0–870) 184.50 (1–986) p = 0.2
Viral Load - 50 (20–94988) 50 (20–93265) p = 0.9
Months of HIV infection - 177 (3–285) 165 (10–285) p = 0.7
Lipodystrophy – MACS score
None n (%) - 162 (14.55%) 22 (10.38%) -
Periferal lipoatrophy n (%) - 500 (44.92%) 72 (33.96%) -
Central adiposity n (%) - 91 (8.18%) 33 (15.57%) -
Mixed form n (%) - 360 (32.35%) 85 (40.09%) -
Ongoing therapy
FI n (%) - 17 (1,53%) 4 (1.89%) -
PI n (%) - 386 (34.68%) 61 (28.77%) -
NNRTI n (%) - 261 (23.45%) 70 (33.02%) -
NRTI n (%) - 704 (63.25%) 146 (68.87%) -
Time exposure to HAART
FI (months) - 8 (0–45) 6 (1–18) p = 0.7
PI (months) - 27 (0–184) 18.50 (0–164) p = 0.047
NNRTI (months) - 24 (0–118) 17.5 (0–108) p = 0.2
Testosterone Deficiency and HIV Infection
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Inclusion criteria. Men aged 18–70 years, with serologically
documented HIV infection, with or without lipodystrophy, and
with ongoing HAART treatment. All patients were considered
eligible if in a stable clinical condition without any acute, severe
illness. The CD4 count was not considered as an inclusion
criterium.
Exclusion criteria. Patients with prior treatment (referred or
documented) with androgens, sex steroids, dehydroepiandrosterone,
antiandrogens, anabolic agents, GnRH agonists, psycholeptic agents
were considered not eligible.
Patients with documented hyperprolactinaemia (serum prolac-
tin above 17.7 ng/mL), hypothyroidism, known pituitary, testic-
ular or adrenal diseases, a previous conventional pituitary surgery
or radiotherapy were considered not eligible.
A history of severe weight loss (more than 15% of the initial
body weight), documented AIDS, cancer, previously documented
diabetes mellitus, severe liver insufficiency or chronic renal failure,
and a fasting glucose above 126 mg/dL, were considered as
further exclusion criteria.
Hormonal and biochemical measurements. Serum LH,
follicle stimulating hormone (FSH), prolactin, estradiol, total T,
thyroid-stimulating hormone (TSH), free thyroxine (fT4), and free
triiodothyronine (fT3) were measured.
Serological status for hepatitis B and C, total cholesterol, high-
density lipoprotein (HDL), and low-density lipoprotein (LDL)
cholesterol, triglycerides, glucose and insulin were assessed.
HIV infection-related parameters. The following para-
meters of HIV infection were evaluated: duration of HIV
infection, quantitative plasma HIV RNA viral load, CD4 cell
count, nadir CD4 count.
Information on both current HAART therapy and prior
antiretroviral class use was obtained at the time of enrollment
and duration of use for each drug was extracted from the medical
records. The drugs were grouped according to the following
antiretroviral classes: fusion inhibitors (FI), protease inhibitors (PI),
non-nucleoside reverse transcriptase inhibitors (NNRTI), and
nucleoside reverse transcriptase inhibitors (NRTI).
Anthropometric evaluation, body composition and
adipose tissue distribution. Demographic characteristics
(age, race, sex) and anthropometric measurements (weight,
height, BMI) were recorded at the time of the first examination
(Table 1). All patients underwent physical examination and
lipodystrophy assessment. Lipodystrophy was defined according
to the MACS (Multicenter AIDS Cohort Study) classification as
‘‘none’’, ‘‘peripheral lipoatrophy’’, ‘‘central adiposity’’ and ‘‘mixed
form’’ [24]. Weight was measured after an overnight fast. Waist
and hip circumferences were calculated as the average of 3
measurements. Height and weight were measured using standard
calibrated instruments. Body mass index (BMI) was calculated as
body weight (kilograms) divided by the square of height (square
meters). Body composition and adipose tissue distribution were
evaluated by both Dual-Energy-X-ray-Absorptiometry (DXA) and
abdominal CT-scan, respectively. An abdominal CT-scan was
performed in order to determine accurately visceral (VAT),
subcutaneous (SAT) and total (TAT) abdominal adipose tissue.
Whole body composition assessment (lean and fat mass) and
measurement of bone mineral density (BMD) were both obtained
by DXA (Hologic-QDR-2000 densitometer, Inc., Waltham, MA).
This technique has an accuracy of 63% for fat mass and 61.5%
for fat-free mass, respectively [25]. BMD was measured at the
femoral neck and lumbar spine.
As per standard protocols, the abdominal adipose tissue
distribution was studied by CT-scan at L4 level, with a single
slice abdominal scan in order to determine VAT and SAT [26],
TAT being the sum of VAT and SAT.
Signs and symptoms of hypogonadism. Subjects were
considered as having a normal BMD, osteopenia, or osteoporosis
when the t-score was $21, between ,21 and .22.5, and
#22.5, respectively [27].
Sexual function was studied in a subset of 247 subjects by means
of the 15-item International Index of Erectile Function (IIEF-15)
questionnaire [28,29]. The IIEF-15 is a widely used, multidimen-
sional self-report instrument for the evaluation of male sexual
function [28]. Scientists recommend IIEF-15 as a primary
instrument in clinical trials of erectile dysfunction (ED) and for
the diagnostic evaluation of ED severity [29]. The IIEF-15
questionnaire addresses five domains of male sexual function:
erectile function, orgasmic function, sexual desire, intercourse
satisfaction, and overall satisfaction with sex life [28,29]. All
responses to the IIEF-15 questions are rated on a 5-point scale,
with a score of 1 representing the worst and 5 the best response.
Criteria for the classification of the gonadal status.
Total serum T was considered as the main marker of biochemical
T deficiency and patients were classified as having normal or low
serum total T according to the threshold value of 300 ng/dL
(10.4 nmol/L) corresponding to the lowest limit of the normal
range of total T assay in the Laboratory of Modena [21] (Figure 1).
According to Tajar et al. [4], serum LH was used to assign patients
to the following categories of biochemical hypogonadism : 1)
eugonadism (normal T and normal LH), 2) compensated
hypogonadism (normal T and high LH), 3) secondary
n.v. Total T$300 ng/dL Total T,300 ng/dL Sig.
NRTI (months) - 53.50 (0–262) 18.50 (0–218) p = 0.004
Total duration of HAART (years) 10 (1–16) 10 (1–14) p = 0.7
Number of patients (n) and relative percentages (%) are reported in Italics, n.v.: normal values, E2: estradiol, BMD: bone mineral density, FI: fusion inhibitors, PI: protease
inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.
doi:10.1371/journal.pone.0028512.t002
Table 2. Cont.
Table 3. Number of patients (n) and relative percentages (%)
of patients according to age and total T serum levels.
Age (years) Entire cohort Total T$300 ng/dL Total T,300 ng/dL
20–29 n (%) 12 (0.9%) 11 (91.7%) 1 (8.3%)
30–39 n (%) 207 (15.6%) 185 (89.4%) 22 (10.6%)
40–49 n (%) 800 (60.4%) 677 (84.7%) 123 (15.3%)
50–59 n (%) 245 (18.5%) 187 (76.4%) 58 (23.6%)
60–69 n (%) 61(4.6%) 53 (86.9%) 8 (13.1%)
doi:10.1371/journal.pone.0028512.t003
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Table 4. Characteristics as median, and minimum and maximum in parenthesis, according to the serum total T threshold of
300 ng/dL in tandem with the LH serum levels (the comparison among groups was performed by nonparametric Kruskal-Wallis
test followed by the Dunn’s multiple-comparison post hoc test when a significant difference was found in order to establish
differences among each group).
Total T$300 ng/dL Total T,300 ng/dL Sig.
n 1325 (%) 1113 (84%) 212 (16%)
E CH SH PH
n 1325 (%) 929 (70%) 184 (14%) 183 (14%) 29 (2%) -
Age (years) 45 (20–69) 45 (30–69) 45 (28–68) 48 (38–66) p = 0.005
Anthropometrical variables
BMI (kg/m2) 23.5 (15.4–43.5) 22.5 (15–32.8) 25.2 (17.2–54.97) 24 (17.6–35.9) p,0.0001
Waist circumference (cm) 86.5 (68–128) 85.5 (63–116) 90 (68–160) 87 (74–119) p,0.0001
Hip circumference 89 (76–116) 88 (71–104) 91 (77.5–141) 90 (79–102) p,0.0001
Waist/hip circumference ratio 0.97 (0.79–1.29) 0.96 (0.82–1.2) 0.99 (0.84–1.2) 0.99 (0.9–1.21) p,0.0001
VAT (cm2) 129 (11–853) 109 (14–446) 151 (29–521) 149 (42–369) p,0.0001
SAT (cm2) 99 (2–807) 76.5 (2–747) 125 (2–595) 118 (10–398) p,0.0001
TAT(cm2) 237 (16–1088) 211 (16–894) 287 (56–909) 292 (16–630) p,0.0001
Total body fat mass (g?1.000) 9.1 (1.1–46.2) 8.3 (1.7–25.3) 11.7 (1.9–43.4) 9.3 (2.9–27.4) p,0.0001
Trunk fat mass- (g?1.000) 5.6 (0.25–47.4) 4.8 (0.93–25.8) 7.0 (1.0–26.6) 6.0 (1.6–27.8) p,0.0001
Total body lean mass- (g?1.000) 55.4 (4.6–82.2) 53.8 (33.5–84.19) 58 (5.4–84.0) 53.3 (41.0–69.7) p,0.0001
Trunk lean mass- (g?1.000) 27.5 (2.4–43.3) 27.2 (4.7–42.7) 28.7 (6.3–45.4) 26.8 (6.6–39.0) p,0.0001
Bone Mineral Density
Lumbar BMD (g/cm2) 1.07 (0.65–1.76) 1.08 (0.65–1.60) 1.07 (0.70–1.66) 1.09 (0.88–1.44) p = 0.9
Lumbar normal BMD n (%) 504 (54.30%) 98 (53.33%) 95 (51.91%) 17 (58.62%) -
Lumbar osteopenic BMD n (%) 346 (37.20%) 66 (35.83%) 73 (39.89%) 10 (34.48%) -
Lumbar osteporosis BMD n (%) 79 (8.50%) 20 (10.84%) 15 (8.2%) 2 (6.90%) -
Femoral BMD (g/cm2) 0.85 (0.32–1.41) 0.85 (0.46–1.29) 0.86 (0.44–1.29) 0.86 (0.63–1.20) p = 0.9
Femoral normal BMD n (%) 341 (36.70%) 73 (39.67%) 67 (36.61%) 11 (37.93%) -
Femoral osteopenic BMD n (%) 503 (54.15%) 85 (46.19%) 102 (55.73%) 15 (51.72%) -
Femoral osteporosis BMD n (%) 85 (9.15%) 26 (14.14%) 14 (7.66%) 3 (10.35%) -
Hormonal measurements
Total T (ng/dL) 478 (300–1098) 553.5 (303–1097) 247 (11–299) 235 (94–299) p,0.0001
LH (mIU/mL) 4.7 (1.4–8.9) 11.65 (9.1–46.2) 3.5 (0.1–8.9) 11.5 (9–40.8) p,0.0001
FSH (mIU/mL) 4.2 (0.3–29.8) 9 (1.4–75.6) 4.2 (0.3–15.7) 14.2 (1.4–42.7) p,0.0001
E2 (pg/mL) 32 (4.6–98) 37 (10–97) 23.5 (10–91) 23 (10–52) p,0.0001
E2/Total T 0.0066 (0.0008–0.022) 0.006 (0.0018–0.018) 0.0101 (0.0036–0.8) 0.0100 (0.0041–0.031) p,0.0001
Infectivological parameters
CD4 Count (cells/mm3) 504 (11–1670) 459 (11–1261) 547.5 (11–2459) 421.5 (34–1320) p,0.0001
CD4 nadir (cells/mm3) 180 (0–870) 110.50 (0–629) 200 (1–986) 115 (4–500) p,0.0001
Viral Load 50 (20–94988) 50 (40–94875) 50 (20–93265) 50 (40–91458) p = 0.5
Months of HIV infection 172 (3–285) 215 (29–279) 162 (10–280) 190 (73–285) p,0.0001
Lipodystrophy – MACS score
None n (%) 148 (15.93%) 14 (7.6%) 21 (11.44%) 1 (3.45%) -
Periferal lipoatrophy n (%) 409 (44.03%) 91 (49.46%) 59 (32.30%) 13 (44.82%) -
Central adiposity n (%) 80 (8.61%) 11 (5.98%) 29 (15.84%) 4 (13.79%) -
Mixed form n (%) 292 (31.43%) 68 (36.96%) 74 (40.42%) 11 (37.94%) -
Ongoing therapy
FI n (%) 15 (1.61%) 2 (1.09%) 2 (1.09%) 2 (6.90%) -
PI n (%) 302 (32.51%) 84 (45.65%) 53 (28,96%) 8 (27.59%) -
NNRTI n (%) 223 (24.00%) 38 (20.65%) 57 (31.15%) 13 (44.83%) -
NRTI n (%) 579 (62.32%) 125 (67.93%) 125 (68.31%) 21 (72.41%) -
Time exposure to drugs
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hypogonadism (low T and low or normal LH), and 4) primary
hypogonadism (low T and high LH) (Figure 1).
Laboratory analysis. Serum total T was assayed by
immunochemioluminescence (ADVIA Centaur, Siemens). The
inter- and intra-assay coefficients of variation were 7.1% and
4.8%, respectively.
Serum LH, FSH, and prolactin were assayed by immuno-
chemioluminescence (ADVIA Centaur, Siemens). The inter-
and intra-assay coefficients of variation were of 3.6% and
2.4% for LH, 5.2% and 2.6% for FSH, 3.9% and 2.5% for
prolactin.
Serum estradiol (E2) was assayed by RIA (Third-Generation
DSL-39100, Diagnostic Systems Laboratories, Inc., Webster, TX,
USA) with a sensitivity of 0.6 pg/mL (2.2 pmol/L), the inter- and
intra-assay coefficients of variation were between 4.1 and 9.9%,
and between 3.4 and 3.9%, respectively.
Total T$300 ng/dL Total T,300 ng/dL Sig.
n 1325 (%) 1113 (84%) 212 (16%)
E CH SH PH
FI (months) 6.50 (0–40) 13 (2–45) 6 (1–18) 9 (6–12) p = 0.055
PI (months) 27 (0–184) 29 (0–172) 18 (0–164) 36 (8–104) p = 0.073
NNRTI (months) 24.50 (0–118) 16 (1–89) 17 (0–108) 31 (1–82) p = 0.037
NRTI (months) 53.50 (0–262) 54.50 (1–225) 18 (0–218) 72.50 (1–180) p = 0.009
NORMAL LH IMPAIRED LH
n 1325 (%) 929 (70%) 396 (30%)
Number of patients (n) and relative percentages (%) are reported in Italics, E: Eugonadism (Normal T and Normal LH), CH: Compensated Hypogonadism (Normal T and
Elevated LH), SH: Secondary Hypogonadism (Low T and Low to Normal LH), PH: Primary Hypogonadism (Low T and Elevated LH),, E2: estradiol, BMD: bone mineral density, FI:
fusion inhibitors, PI: protease inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.
doi:10.1371/journal.pone.0028512.t004
Table 4. Cont.
Figure 2. Gonadal status according to serum total T threshold of 300 ng/dL and LH normal range.
doi:10.1371/journal.pone.0028512.g002
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TSH, fT3, fT4, LDL-, HDL- and total cholesterol, triglycerides,
glucose and insulin were assayed using commercially available kits.
The CD4 cell count was performed by flow cytometry (Becton
Dickinson Immunocytochemistry Systems, San Jose, CA). Quan-
titative plasma HIV RNA viral load was performed using an
ultrasensitive method (Amplicor HIV-1 Monitor Assay, Roche
Molecular Systems, Indianapolis, IN).
Ethics
The study received ethical approval from the Institutional
Review Board of Modena (Comitato Etico di Modena) and all
participants in the study provided written informed consent.
Statistical methods
The nonparametric Mann-Whitney test was used for compar-
isons since most of the variables resulted being not normally
distributed by the Kolmogorov-Smirnov test. The comparison
among groups was performed using the nonparametric Kruskal-
Wallis test (when more than two groups) followed by the Dunn’s
multiple comparison post hoc test when a significant difference
was found in order to establish differences between individual
groups. All the data are shown as median and minimum-
maximum.
We evaluated demographic, anthropometric and hormonal
variables in order to identify possible predictive factors for
circulating serum T. A stepwise, linear, multiple regression
analysis was performed using serum T as the dependent variable,
serum LH as the forced entry variable, followed by age, BMI,
waist circumference, hip circumference, VAT, SAT, TAT, total
body fat, truncal fat, total lean mass and truncal lean mass at
DXA, and HIV infection parameters (months of HIV-infection,
viral load, CD4 count and CD4 nadir) as independent variables.
All multiple regression analyses were based on a single regression
analysis of each predictive independent variable that allowed
identification of candidate predictive variables. A univariate
analysis was performed prior to multivariate analysis. Data are
not shown when the results were not significant. The independent
variables with a significance of p,0.05 were entered into the
regression model. Stepwise, linear multiple regression analysis
using a backwards elimination method was applied to the data,
with p,0.10 as the criterion for a variable to be considered in the
model. The percentage of contribution of a given variable to the
variance of serum T was determined by using the square of the
Pearson correlation coefficient (r2).
Statistical analysis was performed using the ‘Statistical Package
for the Social Sciences’ software for Windows (version 16.0; SPSS
Inc., Chicago, IL) and Sigma Plot (version 11.00 for Windows;
Systat Software Inc., San Jose, CA) for Kruskal-Wallis and the
Dunn’s tests. For all comparisons, a p value,0.05 was considered
statistically significant.
Results
The clinical characteristics of the 1325 patients studied and
information concerning the HIV status of the whole cohort are
summarized in Table 1. According to the MACS score 13.9% of
the enrolled patients were not affected by lipodystrophy, the
remaining subjects being all lipodystrophic (Table 1).
All parameters in the patients, grouped according to serum T
levels, are reported in Table 2 and 3. All parameters in the patients
grouped according to both serum T and LH levels are reported in
Table 3.
Prevalence of biochemical T deficiency and Categories of
Hypogonadism
Total serum T levels were below 300 ng/dL (10.4 nmol/L) in
212 (16%) subjects, with the highest rate of low serum total T in
men aged 40–49 and 50–59. Remarkably, a relevant percentage of
men with impaired total serum T (10.6%) was found in patients
aged 30–39 (Table 3).
Considering both serum total T and LH levels, the patients were
grouped according to their gonadal status in four categories : a)
eugonadism with normal serum T$300 ng/dL and LH
(1.4#LH#8.9 mIU/mL): 929 subjects (70%); b) compensated
hypogonadism with normal serum T$300 ng/dL and elevated
LH (.8.9 mIU/mL): 184 subjects (14%); c) secondary hypogo-
nadism with low serum T,300 ng/dL and low (,1.4 mIU/mL)
to normal (1.4#LH#8.9 mIU/mL) serum LH: 183 subjects
(14%); and d) primary hypogonadism with low serum
T,300 ng/dL and elevated LH (.8.9 mIU/mL): 29 (2%)
subjects (Table 4).
Based on both LH and total T serum levels the prevalence of
biochemical hypogonadism, defined as serum T,300 ng/dL or
an inappropriately high serum LH value with normal serum T,
(comprising patients with compensated, secondary and primary
hypogonadism) increased from 16% to 30% (Figure 2, Table 4).
Table 5. Characteristics of the 247 patients who underwent
International Index of Erectile Function (IIEF-15) questionnaire
(the nonparametric Mann-Whitney test was used for
comparisons since most of the variables resulted not normally
distributed at Kolmogorov-Smirnov test).
n 247 n.v. Median (Min-Max)
Age (years) - 44 (30–69)
Anthropometrical variables
Weight (kg) - 71.0 (42–125)
BMI (kg/m2) 19–25 23.86 (15.3–40.35)
Waist circumference (cm) ,94 87 (70–128)
Hormonal measurements
Total T (ng/dL) 300–900 442 (19.5–989)
LH (mIU/mL) 1.4–8.9 5 (1.1–31.8)
FSH (mIU/mL) 1.7–6.9 4.5 (0.3–48.3)
E2 (pg/mL) 20–40 31 (10–89)
Prolactin (ng/mL) 2.1–17.7 6.5 (2.4–17.3)
IIEF-15 Parameters
Erectile function $25 24 (0–30)
Orgasmic function $9 8 (0–10)
Sexual desire $9 8 (0–10)
Intercourse satisfaction $10 9 (0–15)
Overall satisfaction $9 7 (0–10)
Erectile function ,25 n (%) - 132 (53.44%)
Orgasmic function ,9 n (%) - 129 (52.23%)
Sexual desire ,9 n (%) - 161 (65.2%)
Intercourse satisfaction ,10 n (%) - 132 (53.44%)
Overall satisfaction ,9 n (%) - 210 (85.02%)
Number of patients (n) and relative percentages (%) are reported in Italics, n.v.:
normal values; E2: estradiol. The erectile function is the domain used in clinical
practice to rule out erectile dysfunction when a score of 25 or more is obtained
[29].
doi:10.1371/journal.pone.0028512.t005
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Comparison between groups according to serum total T
Variables including BMI, waist circumference, VAT, SAT,
TAT, total body fat, and truncal fat (p,0.0001), total lean body
mass and trunk lean body mass (p = 0.002), and age (p= 0.006)
were all significantly higher in subjects with serum total
T,300 ng/dL (,10.4 nmol/L) than in subjects with normal
serum total T (Table 2). Serum LH and estradiol were significantly
lower in subjects with serum total T,300 ng/dL than in subjects
with normal serum total T (p,0.0001). No difference was found in
the CD4 count, the CD4 nadir, the viral load, the number of
months of HIV infection, and serum FSH (Table 2) between
subjects with serum total T,300 ng/dL and those with normal
serum total T. No substantial difference was found in the class of
antiretroviral drugs used and in the time of exposure to the drugs
(Table 2), except for the duration of exposure to PI (p,0.05), and
NRTI (p,0.005), which resulted longer in patients with normal T
than in patients with T deficiency (Table 2). The percentage of
men having osteopenia or osteoporosis was unexpectedly similar
between subjects with T deficiency and subjects with normal T.
Furthermore, both femoral and lumbar BMD were not signifi-
cantly different between the two groups (Table 2). The IIEF-15
score, measured in a subset of 247 subjects, often resulted below
the threshold commonly used for defining the presence (,25) or
the lack ($25) of ED [28,29]. This result is consistent with a
remarkably high frequency of ED (53.44%) (Table 5). The mean
score of erectile function was higher in men with normal serum T
than in men with total serum T,300 ng/dL, but the percentage
of men with an insufficient erectile function score remained
elevated (49%) even within men with normal circulating T
(Table 6). The remaining IIEF-15 domains (orgasmic function,
sexual desire, intercourse satisfaction, and overall satisfaction with
sex life) showed a mean below the lower limit of the normal range,
with the percentage of abnormal scores always .50% (Table 5).
All scores of these domains were significantly lower in subjects with
serum T,300 ng/dL than in those with normal T, but the
percentage of men with an insufficient score was elevated even in
men with normal T (Table 6).
Comparison among groups according to categories of
hypogonadism
FSH, estradiol, the E2/T ratio, BMI, waist circumference,
VAT, SAT, TAT, total body fat, truncal fat, total lean body mass,
trunk lean body mass, CD4 count, CD4 nadir, and the number of
months of HIV infection were all significantly different among the
four groups of HIV-infected men designated as eugonadism,
compensated hypogonadism, secondary hypogonadism, and
primary hypogonadism (p,0.0001) (Table 4). Age was signifi-
cantly different among the groups as well (p = 0.005) (Table 4).
Serum estradiol was significantly higher in HIV-infected men
with eugonadism and compensated hypogonadism compared with
men with secondary or primary hypogonadism (p,0.05)
(Figure 3a), but the E2/T ratio was significantly higher in men
with secondary hypogonadism than in subjects with eugonadism
and compensated hypogonadism (p,0.05) (Figure 3b). The E2/T
ratio was significantly higher in HIV-infected men with primary
hypogonadism than in patients with eugonadism or compensated
hypogonadism (p,0.05) (Figure 3b). Both BMI and VAT were
significantly higher in HIV-infected men with secondary hypogo-
nadism compared with subjects with eugonadism or compensated
hypogonadism (p,0.05) (Figures 3c and 3d, Table 4).
Table 6. Characteristics of the 247 patients who filled the International Index of Erectile Function (IIEF-15) questionnaire according
to the threshold of serum total T of 300 ng/dL used to define T deficiency (the nonparametric Mann-Whitney test was used for
comparisons since most of the variables resulted not normally distributed at Kolmogorov-Smirnov test).
n.v. Total T$300 ng/dL Total T,300 ng/dL Sig.
n 247 (%) 220 (89%) 27 (11%)
Age (years) - 45 (30–69) 44 (33–59) p,0.05
Anthropometrical variables
BMI (kg/m2) 19–25 23.7 (15.3–37.7) 25.5 (19.68–40.35) p,0.005
Waist circumference (cm) ,94 87 (70–128) 90 (79–125.5) p,0.005
Hormonal measurements
Total T (ng/dL) 300–900 476 (300–989) 250 (19.5–297) p,0.005
LH (mIU/mL) 1.4–8.9 5.25 (1.4–31.8) 3.7 (1.1–28.4) p,0.005
IIEF-15 Parameters
Erectile function $25 25 (0–30) 18 (1–29) p = 0.003
Orgasmic function $9 8 (0–10) 6 (0–10) p = 0.019
Sexual desire $9 8 (0–10) 7 (2–9) p = 0.002
Intercourse satisfaction $10 9 (0–15) 8 (0–13) p = 0.082
Overall satisfaction $9 7 (0–10) 5 (0–8) p = 0.003
Erectile function ,25 n (%) - 108 (49%) 20 (74.1%) -
Orgasmic function ,9 n (%) - 111 (50.5%) 18 (66.7%) -
Sexual desire ,9 n (%) - 138 (62.73%) 23 (85.2%) -
Intercourse satisfaction ,10 n (%) - 115 (52.27%) 17 (63%) -
Overall satisfaction ,9 n (%) - 183 (83.2%) 27 (100%) -
Number of patients (n) and relative percentages (%) are reported in Italics, n.v.: normal values. The erectile function is the domain used in clinical practice to rule out erectile
dysfunction when a score of 25 or more is obtained [29].
doi:10.1371/journal.pone.0028512.t006
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Lumbar and femoral BMD did not vary among the four groups
(Table 4). Even when patients were grouped according to their t-
score into patients with osteoporosis, osteopenia and normal BMD,
the percentage of men with impaired BMD was similar in the four
groups. The number of months of NNRTI and NRTI exposure was
significantly different among the four groups (p,0.05) (Table 4).
Predictive factors for HIV-related low serum T
Stepwise linear multiple regression analysis for serum total T as the
dependent variable was performed in all 1325 HIV-infected men, using
serum LH as the forced entry variable, and patients age, body
composition parameters, and HIV infection parameters as independent
variables generating four different models (Table 7). The main predictor
of serum total T resulted VAT, followed by age and BMI (Table 7).
Discussion
This study establishes that low serum total T is a common
endocrinological finding (16%) among young/middle-aged HIV-
infected men, mainly with lipodystrophy, treated with HAART
Figure 3. Comparison among groups according to categories of hypogonadism. Serum estradiol (E2), (a), E2/T ratio (b), BMI (c), and VAT (d)
in HIV infected men with eugonadism (normal T and normal LH) compared to compensated hypogonadism (normal T and elevated LH), secondary
hypogonadism (low T and low/normal LH), and primary hypogonadism (low T and elevated LH). The line and the whiskers on the box plots represents
median and Standard Errors, respectively.
doi:10.1371/journal.pone.0028512.g003
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(Table 2, Figure 2). Similar results are usually observed in non
infected men aged 40–69 [4,5]. However, the latter group exhibit
a lower percentage (6%) of androgen deficiency [6,30] than the
HIV-infected men evaluated in this study. Thus, T deficiency
seems to be more common in HIV-infected men than in the
general population [2,6,30]. The absence of a control group is a
limitation of the present study, but the prevalence of T deficiency
in the general population has been extensively studied [1–6,30]
allowing indirect comparison. T deficiency is uncommon before
the age of 40 in non infected men [2], unlike the HIV-infected
men analyzed in this study. Usually, in non infected men younger
than 40 hypogonadism is due to a congenital defect of either the
hypothalamic-pituitary axis, an extremely rare condition, or the
testes. Acquired hypogonadism (e.g. hypothalamic or pituitary
diseases, testicular injuries) is even rarer, such that the prevalence
of hypogonadism before the age of 40 is minimal. In fact,
Vermeulen & Kaufman [2] found only one subnormal serum T in
105 men aged 20–40 years. The finding of low serum total T in
10.6% of patients aged 30–39 (Table 3) suggests that serum T
starts to decline at an early age in HIV-infected men, a conclusion
supported by previous studies [7,12,13,15–17]. Together with
other comorbidities characteristic of HIV infection, the early
decline of serum T should be considered an additional element of
HIV-related premature aging [31].
The percentage of men having low serum T in the present study
is similar to that suggested by other reports [12,17]. The large
sample size investigated by us allows to establish the prevalence of T
deficiency in the context of HIV, improving the consistency of the
limited, available information obtained in previous studies per-
formed on smaller numbers of subjects (less than 300) [7,13–16] and
suffering from the limitations indicated in the introduction.
The novelty of this study lies in the detailed characterization of
T deficiency by using serum T in tandem with serum LH levels in
a large number of HIV-infected men treated with HAART and
mostly lipodystrophic, a comorbidity rarely investigated earlier in
small subsets of subjects [12,14–17]. The results of this study show
that HIV-infected patients often have normal serum total T, but
elevated LH (compensated hypogonadism). This suggests a
possible clinical condition that precedes primary gonadal failure.
This finding indicates that this category of patients requires close
monitoring given their susceptibility to developing overt hypogo-
nadism.
As most of the HIV-infected patients with T deficiency had
inappropriately low serum LH (14%), a primary impairment of
pituitary gonadotropin secretion could be postulated (Figure 2,
Table 4). Thus, the hypothalamic-pituitary axis should be
regarded as the main element involved in the development of T
deficiency in HIV-infected patients, as previously suggested
[11,12,16,22]. Among the factors analyzed, visceral adipose tissue
and BMI are found to be predictive of and inversely related to
serum total T in HIV-infected men. These results suggest that the
amount of VAT may be somewhat involved in suppressing the
hypothalamic-pituitary axis and in decreasing serum LH in HIV-
infected men, as reported in non infected, obese men [4,32,33]. In
the absence of overt obesity, fat redistribution due to HIV-related
lipodystrophy leads, in fact, to increased visceral adiposity. As
estradiol is known to exert a strong inhibitory effect on LH
secretion by acting on both the hypothalamus and the pituitary in
men [34], the increased serum estradiol levels (Figure 3a) related
to adiposity could explain secondary hypogonadism in HIV-
infected men [4,32,33]. High visceral adiposity (Figure 3c,
Figure 3d) and increased T aromatization into estradiol
(Figure 3b), in fact, account for increased serum estradiol levels
in HIV-infected men with secondary hypogonadism. This
information is of clinical relevance since it indicates that T
deficiency in HIV-infected patients with visceral adiposity may
potentially be reversed through weight loss and visceral fat
reduction [4,32].
The models generated by multiple regression analysis, however,
explain only a small percentage of the variance of total serum T,
implying that other factors, not assessed in this setting, in addition
to adiposity, could contribute to the circulating amount of T in
HIV-infected men. Among them, the virus itself and the
medications combined in HAART schemes could be implicated
in the suppression of the hypothalamic-pituitary-gonadal axis
[13,14,16,22,35]. However, current knowledge in the field remains
extremely poor and requires further investigation [22,35].
Recently, circulating serum T has been suggested to be a marker
of illness associated to the general state of health, since low
circulating levels of T are often found in men with poor general
health [23,33,36]. Accordingly, the greater the number of
comorbidities, the higher the frequency of T deficiency [33].
Therefore, the hypothesis should be considered that the
concomitant presence of several comorbidities [37] and the
corresponding worsening of general health, both common in the
context of HIV, may have contributed to the high incidence of
hypogonadism observed in this study. Accordingly, HAART
treatment ensures viral suppression and avoids AIDS development
[37] but does not fully restore health [37,38]. The persistent
imbalance of the immune system, the chronic inflammation state
and the toxicity of the drugs are responsible for several non AIDS-
related complications resembling those occurring during aging in
non infected subjects [38]. Their onset at an early age in HIV-
infected men supports the hypothesis of premature aging [31,38].
T deficiency could be included in this process, but presently it is
not known whether the premature decline in serum T in HIV-
Table 7. Stepwise linear multiple regression estimating
predictive factors for serum total T in the HIV-infected men.
Dependent variable: Testosterone
Stepwise linear multiple regression Variables entering the model
b P level r2
Model 1
LH (forced entry) +6.947 ,0.001 0.032
Model 2
LH (forced entry) +6.441 ,0.001 0.055
VAT 20.360 ,0.001
Model 3
LH (forced entry) +6.672 ,0.001 0.061
VAT 20.304 ,0.001
Age 22.316 0.003
Model 4
LH (forced entry) +6.424 ,0.001 0.065
VAT 20.200 0.011
Age 22.316 0.003
BMI 24.364 0.010
b: coefficient of regression. P level: significance of correlation. r2: Pearson
correlation coefficient. The variables considered into stepwise multiple linear
regression are: LH, VAT, age, BMI, waist circumference, hip circumference, SAT, TAT,
total body fat at DXA, truncal fat at DXA, total lean mass at DXA, truncal lean
mass at DXA, months of HIV-infection, viral load, CD4 count, CD4 nadir.
doi:10.1371/journal.pone.0028512.t007
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infected men reflects premature aging or if it depends on the
health status in terms of concomitant comorbidities and/or frailty.
The study design of this study was not specifically addressed at
identifying the mechanisms involved in premature aging of the
hypothalamic-pituitary-gonadal axis, although we could prove that
the gonadal status in young/middle-aged HIV-infected patients
resembles that of non infected older men. This process of
premature aging in HIV-infected men is known to affect
neurocognitive aspects [39], the cardiovascular system [38] and
tumorigenesis [40] in a manner otherwise typical of older men
[31,38]. Accordingly, gonadal function may be affected by these
multifactorial events (e.g. the presence of several comorbidities, an
altered pattern of chronic inflammation, immune system failure
and viral replication), which are responsible for the acceleration of
the aging process [31,38–40]. Alterations in the immune system
and chronic inflammation are known to interfere with the
hormonal control at central hypothalamic-pituitary level; similarly,
adipokines produced by the adipose tissue may exert much the
same effect [32]. We speculate that some of these mechanisms
operate in HIV-infected men showing increased visceral fat,
alterations in the immune function and a chronically activated
inflammation [38].
The lack of the SHBG measurement and, therefore, of free
serum T represents a limitation of this study. The use of total
serum T alone may have resulted in an underestimation of the
prevalence of biochemical hypogonadism since calculated free
serum T has been suggested as more appropriate in the context of
HIV due to the possible rise in serum SHBG in these patients [17].
Changes of SHBG levels in the HIV context remain, however,
controversial, since increases in SHBG with concomitant weight
loss, [7,17,41,42], decreases in SHBG [43], and no modifications
of serum SHBG [13] have been described. Testing of serum total
T has several advantages, in clinical practice, since it is widely
available, accurate, unexpensive and reliable [44]. On the other
hand, the accuracy of calculated free T has recently been
questioned because of the possible sum of errors deriving from
both serum total T and SHBG assays [44–46]. The measurement
of serum T in a single blood sample is another limitation of the
present study, since serum T may vary overtime and two different
measurements are required in clinical practice to determine
biochemical T deficiency with certainty [21,23]. A single T
measurement could possibly result in an overestimation of samples
with low serum total T, since it is documented that a second
measurement may provide results falling within the normal range
[21,47]. Hence, a single quantification of serum T fairly reflects
the amount of circulating T and provides consistent and reliable
information if performed on a large sample of patients, as
documented in large epidemiological studies [48]. In the present
study, the largest and most comprehensive dataset on serum T in
the context of HIV, the high number of patients studied
counterbalances, at least in part, the tendency to overestimate
low serum T when using a single measurement. In addition, the
single measurement of serum total T was coupled with the
corresponding LH value in each patient enrolled, thus obtaining
much complete information on the real gonadal status in these
patients. In clinical practice, the confirmation of androgen
deficiency by means of a second serum T measurement is a valid
procedure, especially prior to starting T replacement treatment in
order to avoid unnecessary overtreatment [21,22]. The present
study reveals that signs and symptoms of hypogonadism and the
biochemical evidence of hypogonadism can be uncoupled in the
context of HIV infection. This results from the concomitance of
several confounding factors, such as the high prevalence of sexual
problems and the significant bone loss occurring in HIV-infected
men, irrespective of the patient’s gonadal status [27,49,50].
Accordingly, we did not find significant differences in BMD,
osteopenia, osteoporosis or in the percentage of impaired IIEF-15
scores between HIV-infected men with or without T deficiency.
All these elements result in the overlap of signs and symptoms of
androgen deficiency with those related to HIV infection
[27,49,50]. This result confirms the low specificity of signs and
symptoms of androgen deficiency in men with HIV infection
[17,51], suggesting that confounding elements should be consid-
ered when diagnosing androgen deficiency in this context [33], as
in other chronic illnesses [8,49]. While, in non infected men, the
biochemical evidence of low serum T reaches clinical relevance
only in the presence of symptoms of androgen deficiency [30,33],
the clinical diagnosis of T deficiency in HIV is complicated by the
low specificity of signs and symptoms of hypogonadism. The latter,
in fact, loss their value in confirming the clinical diagnosis of
hypogonadism when low serum T is already documented in HIV-
infected men.
In conclusion, T deficiency is frequent in young/middle-aged
HIV-infected men with lipodystrophy, as are other endocrine
diseases in the context of HIV infection [27,35,37]. T deficiency
seems to occur at a younger age than would be expected among
non infected subjects and may be one element of the process of
premature or accelerated aging associated with HIV infection
[31,38]. Premature serum T decline is associated with inappro-
priately low/normal LH and visceral body fat excess, suggesting
that weight loss could improve, in some cases, circulating
testosterone in HIV-infected patients with increased visceral
adiposity. Whether or not HIV-infected men with low serum T
are truly hypogonadic and need T replacement remains unclear,
but the possible, close relationship between comorbidities, the
general state of health and the low serum T as well as the difficulty
of diagnosing hypogonadism should not be underestimated.
Accordingly, in men with HIV infection and concomitant low
serum T, caution is needed in diagnosing true hypogonadism as
well as in prescribing T replacement treatment on a large scale . At
present, the premature onset of T deficiency in HIV-infected men
should be of concern in clinical practice and how to select patients
who could benefit from testosterone treatment remains a
challenging and a yet unresolved issue, along with the risk of
overtreatment and its possible side effects.
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